Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
Nasopharyngeal carcinoma is one of the high incidence head and neck cancer in Southeast Asia.
Radiotherapy is the main treatment for nasopharyngeal carcinoma, and its response rate can
reach 80~90%. However, for radiotherapy resistant patients with metastasis and recurrence,
the survival prognosis decreased significantly, and the 5-year overall survival rate was only
20% - 40%. Tranilast is an anti-allergic drug, which is clinically used to treat bronchial
asthma and can inhibit fibroblasts α- SMA and type I collagen expression. Through experiments
in vivo and in vitro, the investigators' research group has proved that Tranilast can inhibit
the activity of tumor related fibroblasts, reduce the radiotherapy resistance of
nasopharyngeal carcinoma, and has the radiosensitizing effect of nasopharyngeal carcinoma.
This result has been published in J exp Clin cancer res (if=11.16). The investigators plan to
carry out the clinical transformation of basic research, carry out a prospective intervention
phase II clinical trial, compare the objective remission rate of patients with recurrent
nasopharyngeal carcinoma treated with previous radiotherapy, and explore the safety and
effectiveness of using Tranilast as a radiotherapy sensitizer for radiotherapy to resist the
treatment of nasopharyngeal carcinoma.